## Opening Ceremony and CTAD Lifetime Achievement Award

Awarded to Maria Carrillo, Ph.D., in recognition for her extensive contributions to the advancement of AD clinical trials.

## Symposium 1: Development of a Vaccine for Prevention and Treatment of Alzheimer’s Disease

**Chair:** Richard Mohs, Global Alzheimer's Platform Foundation, United States

**Presentation 1:** Past and current vaccine and immunotherapy development in Alzheimer's disease  
*Suzanne Hendrix, Pentara Corporation, United States*

**Presentation 2:** UB-311, a novel UBTh® amyloid beta peptide vaccine in development for Alzheimer’s Disease  
*Jeffrey Cummings, CNS Innovations, United States*

**Presentation 3:** The promise of blood-based biomarkers in the evaluation, approval and affordability in Alzheimer’s prevention therapies  
*Eric Reiman, Banner Alzheimer’s Institute, United States*

## Oral communications

**OC1 Efficacy and Safety of AXS-05, a Novel Oral NMDA Receptor Antagonist with Multimodal Activity, in the Treatment of Alzheimer’s Disease Agitation: Results of the ADVANCE-1 Trial**  
*Cedric O GORMAN (1), Amanda JONES (1), Jeffrey CUMMINGS (2), Herriot TABUTEAU (1) - (1) Axsome Therapeutics Inc., United States, (2) Center For Neurodegeneration And Translational Neuroscience; Cleveland Clinic Lou Ruvo Center For Brain Health; Cleveland Clinic Lerner College Of Medicine, United States*

**OC2 The AHEAD 3-45 Study of BAN2401 in Preclinical Alzheimer’s Disease: Study Design and Initial Screening Results**  
*Reisa SPERLING (1), Rebecca AMARIGLIO (1), Shobha DHADDA (2), Michael C. DONOHUE (3), Michael C. IRIZARRY (2), Cecily JENKINS (3), David JIANJUN LI (2), Keith A. JOHNSON (4), Lynn D. KRAMER (2), Stephen KRAUSE (2), Kathryn PAPP (1), Martin RABE (2), Rema RAMAN (3), Dorene RENTZ (1), Gopalan SETHURAMAN (3), Chad J. SWANSON (2), Jin ZHOU (2), Paul S. AISEN (3) - (1) Brigham And Women's Hospital, Massachusetts General Hospital, Harvard Medical School, United States, (2) Eisai, United States, (3)University Of Southern California, United States, (4) Massachusetts General Hospital, Brigham And Women's Hospital, Harvard Medical School, United States*

**OC3 EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer’s disease**  
*Carmen CASTRILLO-VIGUERA, Spyros CHALKIAS, Patrick BURKETT, Shuang WU, Huaihou CHEN, Katie HARRISON, Carol YURGALEVITCH, Samantha BUDD HAEBERLEIN - (1) Biogen, United States*
OC4 Phase 2 study of tilavonemab, an anti-tau antibody, in early Alzheimer’s disease: study design, baseline demographics, and biomarker profiles

Nahome FISSEHA (1), Anthony BANNON (1), Hana FLORIAN (1), Qi GUO (1), Ziyi JIN (1), Beatrice RENDENBACH-MUELLER (1), Deli WANG (1), Dustin WOOTEN (1), Arnold STEVEN (2) - (1)Abbvie Inc., United States, (2)Massachusetts General Hospital, United States

OC5 Synaptic density is associated with cognitive performance in Alzheimer’s disease: a PET imaging study with [11C]UCB-J

Christopher VAN DYCK, Adam MECCA, Emily SHARP, Ryan O’DELL, Emmie BANKS, Hugh BARTLETT, Ming-Kai CHEN, Mika NAGANAWA, Takuya TOYONAGA, Joanna HARRIS, Gessica NI, Wenzhen ZHAO, Nabeel NABULSI, Brent VANDER WYK, Yiyun HUANG, Amy ARNSTEN, Richard CARSON - (1)Yale School Of Medicine, United States

OC6 Ketones improve brain energetics and cognitive performance in mild cognitive impairment: Final results of the 6-month Benefic trial in MCI

Stephen CUNNANE (1), Mélanie FORTIER (1), Alexandre CASTELLANO (1), Valérie ST-PIERRE (1), Étienne MYETTE-CÔTÉ (1), Maggie ROY (1), Marie-Christine MORIN (1), Francis LANGLOIS (1), Carla DELANNOY (2), Bernard CUENOUD (2), Christian BOCTI (1), Tamas FULOP (1) - (1)Université De Sherbrooke, Canada, (2)Nestlé Health Science, Switzerland

OC7 Longitudinal 18F-RO948 PET and biomarker driven enrichment strategies for tau pathology in AD clinical trials

Antoine LEUZY (1), Gregory KLEIN (2), Nicholas CULLEN (3), Niklas MATTSSON-CARLGREN (1), Shorena JANELIDZE (1), Sebastian PALMQVIST (1), Xavier TEITSMA (1), Olof STRANDBERG (1), Preciosa COLOMA (2), Edilio BORRONI (2), Erik STOMRUD (1), Ruben SMITH (1), Rik OSSENKOPPELE (1), Oskar HANSSON (1) - (1)Lund University, Sweden, (2)F. Hoffmann-La Roche Ltd, Switzerland, (3)Lund University - Lund (Sweden), Sweden

OC8 Voxel based morphometry reveals a distributed pattern of grey matter volume changes following verubecestat exposure in the EPOCH trial

David SCOTT (1), Katarzyna ADAMCZUK (1), Mehul SAMPAT (1), Ha PHAM (1), James KOST (2), Michael EGAN (2), Cyrille SUR (2) - (1)Bioclinica, United States, (2)Merck, United States
### Thursday, November 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 – 8:30 a.m. | **Keynote 1: “Plasma biomarkers in the diagnosis and longitudinal follow-up of Alzheimer’s Disease”**  
*Oskar Hansson, MD, PhD - Lund University, Sweden* |
| 8:30 – 9:30 a.m. | **Symposium 2: Latest Advances: Blood and Imaging Biomarkers of Tau in Alzheimer’s Patients**  
*Chair: Howard FILLIT, Alzheimer’s Drug Discovery Foundation, United States*  
**Presentation 1: Phosphorylated Tau in Blood can Transform Alzheimer’s Disease Research and Clinical Trials**  
*Jeffrey DAGE, Eli Lilly & Company, United States*  
**Presentation 2: Tau Imaging in Alzheimer’s Disease Clinical Trials and in AD research**  
*Michael DEVOUS, Avid Radiopharmaceuticals, United States*  
**Presentation 3: What Could Tau Biomarker Research in Alzheimer’s Disease Mean for Patients?**  
*Takeshi IWATSUBO, University Of Tokyo, Japan* |
| 9:30 – 10:45 a.m. | **Oral communications**  
**OC9 BAN2401 And Aria-E In Early Alzheimer’s Disease: Pharmacokinetic/Pharmacodynamic Time-To-Event Analysis From The Phase 2 Study In Early Alzheimer’s Disease**  
*Larisa REYDERMAN (1), Seiichi HAYATO (2), Yong ZHANG (1), Osamu TAKENAKA (2), Sanae YASUDA (1), Edgar SCHUCK (1), Akihiko KOYAMA (1), Chad SWANSON (1), Ziad HUSSEIN (1) - (1)Eisai Inc., United States, (2)Eisai Co., Ltd, Japan*  
**OC10 The analytical assessment of three research Simoa assays for plasma measurement of phosphorylated tau (pT181, pT217, pT231)**  
*Jeroen VANBRABANT (1), Erik STOOPS (1), Kaj BLENNOW (2, 3), Eugeen VANMECHELEN (1) - (1)Adx Neurosciences Nv, Belgium, (2)Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy At The University Of Gothenburg, Sweden, (3)Clinical Neurochemistry Laboratory, Sweden*  
**OC11 Baseline Characteristics For CLARITY-AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating BAN2401 In Early Alzheimer’s Disease**  
*Shau Yu LYNCH (1), Michael IRIZARRY (1), Shobha DHADDA (1), Yong ZHANG (1), Jinping WANG (1), Tanya BOGOSLOVSKY (1), Larisa REYDERMAN (1), June KAPLOW (1), Heather BRADLEY (1), Martin RABE (1), Keiichiro TOTSUKA (2), Lynn KRAMER (1), Harald HAMPEL (1), Chad SWANSON (1) - (1)Eisai Inc., United States, (2)Eisai Co., Ltd, Japan*  
**OC12 Complementary analyses of the AMBAR trial: plasma exchange treatment slows cognitive, functional and global decline of amyloid positive and negative individuals**  
*Jessie NICODEMUS-JOHNSON (1), Suzanne HENDRICKX (1), Miquel BARCELÓ (2), Mercè BOADA (3, 4), Oscar LOPEZ (5), Laura NUÑEZ (2), Carlota GRIFOLS (2), Antonio PÁEZ (2) - (1)Pentara Corporation, United States, (2)Alzheimer’s Research Group, Grifols, Spain, (3)Research Center And Memory Clinic, Fundación Ace, Institut Català De Neuromèdiques Aplicades-Universitat Internacional De Catalunya, Spain, (4)Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Spain, (5)Departments Of Neurology And Psychiatry, University Of Pittsburgh School Of Medicine, United States* |
OC13 LipiDiDiet results: 3-year evaluation of Fortasyn Connect in individuals with prodromal Alzheimer’s Disease

Tobias HARTMANN (1, 2), Alina SOLOMON (3, 4, 5), Pieter VISSE (6, 7), Suzanne HENDRIX (8), Kaj BLENNOW (9, 10), Miia KIVIPELTO (3, 11, 5), Hilkka SOININEN (12, 13) - (1) Deutsches Institut für Demenz Prävention (didp), Saarland University, Germany, (2) University, Germany, (3), Institute Of Clinical Medicine, University Of Eastern Finland, Finland, (4) Care Sciences and Society, Karolinska Institutet, Sweden, (5) Clinical Trials Unit, Karolinska University Hospital, Sweden, (6) Alzheimer Centre, Amsterdam Neuroscience, VU University Medical Center, The Netherlands, (7) Alzheimer Centre Limburg, University of Maastricht, The Netherlands, (8) Pentara Corporation, United States, (9), Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At University Of Gothenburg, Sweden, (10) Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden, (11) Care Sciences and Society, Karolinska Institutet, Sweden, (12) Neurocentre, Kuopio University Hospital, Finland, (13) Institute of Clinical Medicine, University of Eastern Finland, Finland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 – 11:15</td>
<td>Coffee break and poster session</td>
</tr>
</tbody>
</table>
| 11:15 – 12:15 | Symposium 3 Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s disease Platform (TRC-PAD Platform)  
Chair: Sarah WALTER, Alzheimer's Therapeutic Research Institute, University Of Southern California, United States  
Presentation 1: Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s disease Platform (TRC-PAD Platform) - Design and Scientific rationale  
Paul AISEN, Alzheimer's Therapeutic Research Institute, University Of Southern California, United States  
Presentation 2: Building the Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD) - Experience from the first three years  
Sarah WALTER, Alzheimer's Therapeutic Research Institute, University Of Southern California, United States  
Presentation 3: Accelerating Participant Recruitment in Alzheimer’s Disease Clinical Trials using adaptive statistical modeling  
Oliver LANGFORD, Alzheimer's Therapeutic Research Institute, University Of Southern California, United States  
Presentation 4: TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology  
Gustavo JIMENEZ-MAGGIORA - Alzheimer's Therapeutic Research Institute, University Of Southern California, United States |
| 12:15 – 12:45 | Keynote 2 The LEADS Program: a new opportunity for therapeutic research  
Liana Apostolova, MD - Indiana University School of Medicine, USA |
| 12:45 – 1:45  | Lunch and poster session                                                 |
Oral communications

OC14 Comparison of Aducanumab, Solanezumab and BAN2401 Using a Global Statistical Test for Assessing Impact on Overall Strength of Evidence
Samuel DICKSON (1), Sean HENNESSEY (1), Jacob NEFF (2), Tess SYNGERGAARD (2), Madison EARNSHAW (2), Suzanne HENDRIX (1) - (1)Pentara Corporation, United States, (2)Brigham Young University, United States

OC15 Top line results from the PRESENCE study of a dopamine D1 receptor positive allosteric modulator (D1PAM), mevidalen, for the treatment of Lewy Body Dementia (LBD)
Kevin BIGLAN, Leanne MUNSIE, Kjell SVENSSON, Paul ARDAYFIO, Melissa PUGH, John SIMS, Mark MINTUN - (1)Eli Lilly, United States

OC16 Effects of omega-3 (n-3) polyunsaturated fatty acids (PUFA) on cerebral white matter hyperintensities, medial temporal lobe atrophy and white matter integrity in older non-demented adults: A 3-year randomized-controlled phase 2 trial
Gene BOWMAN (1), Charles MURCHISON (2), Lisa SILBERT (1), Hiroko DODGE (1), Kirsten HAGEN (1), Jason DAVID (1), David LAHNA (1), Jeffrey KAYE (1), Joseph QUINN (1), Lynne SHINTO (1) - (1)Oregon Health & Science University, Department Of Neurology, United States, (2)University Of Alabama, Birmingham, United States

OC17 Repeated Smartphone-Based Memory Assessment: the Boston Remote Assessment for Neurocognitive Health (BRANCH)
Kate PAPP (1), Aubryn SAMAROO (2), Hsiang-Chin CHOU (2), Rachel BUCKLEY (1), Dorene RENTZ (1), Reisa SPERLING (1), Rebecca AMARIGLIO (1) - (1)Harvard Medical School, United States, (2)Massachusetts General Hospital, United States

OC18 MEDI1814, a beta-amyloid 42-specific antibody, lowered neurofilament light plasma levels in patients with mild-moderate Alzheimer’s disease
Craig SHERING (1), Thor OSTENFELD (2), Michael POMFRET (2), Andrew BILLINTON (3), Iain CHESSELL (2), Keith TAN (2), Nigel BRAYSHAW (4), Kaj BLennow (5), Staffan Persson (5), Fanni Natanegara (6), Yingdong Feng (6), John Sims (6), Jeffrey Dage (6) - (1)Astrazeneca, United States, (2)Astrazeneca, United Kingdom, (3)Former Astrazeneca Employee, (4)Empiridat Ltd, United Kingdom, (5)University Of Gothenburg, Sweden, (6) Eli Lilly And Company, United States

OC19 IMPACT-AD: A novel clinical trials training program
Tyler BERKNESS (1), Maria C. CARRILLO (2), Kristina MCLINDEN (3), Reisa SPERLING (4, 5), Ronald PETERSEN (6), Paul AISEN (1), Heather SNYDER (2), Laurie RYAN (3), Joshua D. GRILL (7), Rema RAMAN (1) - (1)Alzheimer’s Therapeutic Research Institute, United States, (2)Alzheimer’s Association, Division Of Medical And Scientific Relations, United States, (3)National Institute On Aging, Dementias Of Aging Branch, United States, (4)Massachusetts General Hospital, Harvard Medical School, United States, (5)Massachusetts General Hospital, Harvard Medical School, United States, (6)Mayo Clinic, United States, (7)University Of California At Irvine, United States

OC20 Relationship between pimavanserin exposure and psychosis relapse in patients with dementia-related psychosis: clinical results and modeling analysis from the phase 3 HARMONY study
Mona DARWISH (1), Erin P. FOFF (1), Julie PASSARELL (2), David JAWOROWICZ (2), Mark FORMAN (1), Joel OWEN (1), Srdjan STANKOVIC (1) - (1)ACADIA Pharmaceuticals, Inc., United States, (2)Cognigen Corporation, A Simulations Plus Company, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 – 4:45 p.m.</td>
<td>Late-breaking communications</td>
</tr>
<tr>
<td>4:45 – 5:15 p.m.</td>
<td>Coffee break and poster session</td>
</tr>
<tr>
<td>5:15-6:15 p.m.</td>
<td>Late-breaking communications</td>
</tr>
</tbody>
</table>

**OC21 Clinical phase I data and five successful PoC studies in transgenic and non-transgenic animal models of AD for the first anti-prionic drug candidate for Alzheimer’s disease**

Dieter WILLBOLD (1, 2), Janine KUTZSCHE (1), Sarah SCHEMMERT (1), Antje WILLUWEIT (3), Dagmar JÜRGENS (1) - (1)Forschungszentrum Jülich, Germany, (2)Heinrich-Heine-Universität Düsseldorf, Germany, (3)Forschungszentrum Jülich, Germany

**OC22 Monoclonal antibodies against amyloid-β in Alzheimer’s disease. A meta-analysis of phase III clinical trials**

Konstantinos AVGERINOS, Luigi FERRUCCI, Dimitrios KAPOGIANNIS - (1) National Institute On Aging, National Institutes Of Health, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 – 9:00 a.m. | Symposium 4 Accelerating the Development of Novel Biomarkers for Alzheimer’s Disease and Related Dementias: A Progress Report From The Diagnostics Accelerator Initiative  
Howard FILLIT (1), Niranjan BOSE (2) Henrik Zetterberg (3) (4), Simon Lovestone (5), Rhoda Au (6)- (1)Alzheimer’s Drug Discovery Foundation, United States, (2)Gates Ventures Llc, United States, (3) University of Gothenburg, Sweden, (4) University College London, United Kingdom, (5) Janssen-Cilag, United Kingdom, (6) Boston University Schools of Medicine, United States |
| 9:00-9:30 a.m. | Keynote 3: Remote assessment of cognitive and clinical decline  
Jeffrey Kaye, MD – Layton Aging and Alzheimer’s Disease Center, School of Medicine, Oregon Health and Science University, United States |
| 9:30-10:30 a.m. | Oral communications  
OC23 Increased Power with Averaging Two Scores at Baseline and End of Study for Two Primary Outcomes: ADAS-cog and ADCS-CGIC  
Newman KNOWLTON (1), Sam DICKSON (1), Ron THOMAS (2), Lon SCHNEIDER (3), Richard KENNEDY (4), Marc CANTILLON (5), Suzanne HENDRIX (1) - (1)Pentara Corporation, United States, (2)UCSD, United States, (3)UCSD, United States, (4)JUAB, United States, (5)Robert Wood Johnson Medical School, United States  
OC24 A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different Tauopathy Syndromes  
Adam BOXER (1), Peter LJUBENKOV (1), Lawren VANDEVREDE (1), Julio ROJAS (2), Richard TSAI (3), Mary KOESTLER (1), Lauren FISHER (1), Hannah WIEST (1), Catherine WANG (1), Howard ROSEN (4), Danielle GRAHAM (5), Tien DAM (5) - (1)University Of California, San Francisco, United States, (2)University Of California, San Francisco - San Francisco (United States), United States, (3)Denali Therapeutics, United States, (4)University Of California, San Francisco-San Francisco (united States), United States, (5)Biogen Inc., United States |
<p>| 9:30-10:30 a.m. | Coffee break and poster session |
| 11:00 – 11:45 a.m. | Late breaking communications |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Session Details</th>
</tr>
</thead>
</table>
| 11:45 a.m. – 12:15 p.m. | Keynote 4 Implementing the lessons of epidemiology  
Kristine Yaffe, MD - University of California at San Francisco, United States |
| 12:15 – 1:15 p.m.    | Lunch and poster sessions                                                              |
| 1:15 – 2:45 p.m.     | Oral communications                                                                    |
|                      | **OC27** Phase 2/3 GAIN trial of COR388 (atuzaginstat), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease: Update and Baseline Data  
*Michael DETKE* - (1) Cortexyme, United States |
|                      | **OC28** The Methodology and Probability of Recruitment and Enrollment into Phase 2 and 3 Alzheimer’s Disease and Mild Cognitive Impairment Clinical Research Trials  
*Domonique NATHAN, Devon ANDERSON, Raza WARRAICH, Evan CASSAR, David WEISMAN* - (1)Abington Neurological Associates, United States |
|                      | **OC29** Misfolding of Aβ as precise plasma structure biomarker for preclinical Alzheimer’s  
*Klaus GERWERT* (1, 2) - (1) Ruhr University Bochum, Germany, (2) Center for Protein Diagnostics, Germany |
|                      | **OC30** The Amsterdam Instrumental Activities of Daily Living Questionnaire in prodromal vs. mild Alzheimer’s disease: Analysis of baseline data from the Tauriel study  
|                      | **OC31** Magnetic resonance imaging measures of brain atrophy across the EXPEDITION trials in mild and moderate Alzheimer’s disease dementia  
|                      | **OC32** The ADNI Diversity Taskforce: A closer look at the screening and enrolment of underrepresented populations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)-3  
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 2:45 pm – 3:45 p.m. | **Symposium 5 Composite cognitive endpoints for clinical trials in neurodegenerative disease**  
Chair: Michael DONOHUE, Keck School of Medicine, United States  
Presentation 1: Conceptual and methodological issues related to composite development and validation  
Terry GOLDBERG, Columbia University Medical Center, United States  
Presentation 2: The PACC: Development, validation, and current-status  
Kathryn V. PAPP, Brigham And Women’s Hospital, United States  
Presentation 3: The HD-CAB: Data summarization approaches, and clinical meaningfulness  
Julie C. STOUT, School of Psychological Sciences At Monash University, Australia |
| 3:45 – 4:15 pm   | Coffee break and poster session                                         |
| 4:15 – 5:30 pm   | **Late Breaking communications**                                        |
Saturday, November 7

**Oral communications**

**OC33** Remote Collection of Over 600 Blood Samples from Participants Enrolled in an Online Registry in One Month During the COVID Epidemic
Juliet FOCKLER (1), Taylor HOWELL (1), Aniekan EKANEM (1), Derek FLENNIKEN (2), Alexander HAPP (2), Miriam ASHFORD (2), Jacqueline HAYES (2), Diana TRURAN (2), R. Scott MACKIN (1), Kaj BLENNOW (3), Daniel GESCHWIND (4), Eran HALPERIN (4), Giovanni COPPOLA (5), Rachel NOSHENY (1), Michael WEINER (1) - (1)Ucsf, United States, (2)Ncire, United States, (3)University Of Gothenburg, Sweden, (4)Ucla, United States, (5)Regeneron Genetic Center, United States

**OC34** Baseline characteristics of the Mild Alzheimer's Disease Patient Population Included in the Ongoing Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Phase 1b Study of Intrathecally Administered Tau Antisense Oligonucleotide (ISIS 81490)
Catherine MUMMERY (1), Candice JUNGE (2), Laury MIGNON (2), Katrina MOORE (2), Chris YUN (2), Dan LI (2), Dan NORRIS (2), Becky CREAN (2), Elena RATTI (3), Ellen HUANG (3), Roger LANE (2) - (1)University College London, United Kingdom, (2)Ionis Pharmaceuticals Inc., United States, (3)Biogen Pharmaceuticals Inc., United States

**OC35** Evaluation of Liraglutide in treatment for Alzheimer's disease
Paul EDISON (1, 2), Grazia FEMMINELLA (1), Clive HOLMES (3), Craig RITCHIE (4), Basil RIDHA (5), Zuzana WALKER (6), Christian HOLSCHER (7), Eleni FRANGOU (6), Sharon LOVE (6), Robert LAWRENCE (8), Brady MCFARLANE (3), George TADROS (9), Hilary ARCHER (10), Elizabeth COUTHLAND (10), Benjamin UNDERWOOD (11), Paul KORANTENG (12), Salman KARIM (13), John HARRISON (14), Peter PASSMORE (15), Clive BALLARD (16) - (1)Imperial College London, United Kingdom, (2)Cardiff University, United Kingdom, (3)University Of Southampton, United Kingdom, (4)University Of Edinburgh, United Kingdom, (5)Brighton And Sussex University Hospitals, United Kingdom, (6)University College London, United Kingdom, (7)Henan University Of Chinese Medicine, China, (8)St George's University Of London, United Kingdom, (9)University Of Bath, United Kingdom, (10)University Of Bristol, United Kingdom, (11)University Of Cambridge, United Kingdom, (12)Northamptonshire NHS Trust, United Kingdom, (13)Lancashire Care NHS, United Kingdom, (14)Kings College London, United Kingdom, (15)Queens University, Belfast, United Kingdom, (16)University Of Exeter, United Kingdom

**OC36** Translational pharmacology of IBC-Ab002, a novel fully human anti-PD-L1 antibody, for treating Alzheimer’s disease
Eti YOLES (1), Kuti BARUCH (1), Alexander KERTSER (1), Omri MATALON (1), Ofir FURSHT (1), Shai BRAIMAN (1), Carol DAVID (1), Elizeer SHOCHAT (2), Jesse CEDARBAUM (3, 1), Michal SCHWARTZ (4, 1) - (1)Immunobrain Checkpoint Ltd., Israel, (2)Shochat Pharma Services, Switzerland, (3)Coeruleus Clinical Sciences Llc, United States, (4)Weizmann Institute Of Science, Israel

**OC37** Detecting meaningful change in everyday functioning: A mixed-methods approach to establish clinical meaningfulness of changes on the Amsterdam IADL questionnaire
Mark DUBBELMAN (1), Merike VERRUP (1), Roos JUTTEN (1), Caroline TERWEE (2), Leonie VISSER (1, 3), Wiesje VAN DER Flier (1), Philip SCHELTENS (1), Sietske SIKKES (1, 4) - (1)Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam Umc, The Netherlands, (2)Department Of Epidemiology And Biostatistics, Amsterdam Umc, The Netherlands, (3)Amsterdam Public Health research institute, University of Amsterdam, Amsterdam Umc, The Netherlands, (4)Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, The Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 – 10:30</td>
<td>Late breaking communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Coffee break and poster session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 a.m. –</td>
<td>Oral communications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 p.m.</td>
<td>Lunch and poster session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**OC38 The electronic Person-Specific Outcome Measure (ePSOM) development program**
Craig RITCHIE (1), Stina SAUNDERS (1), Graciela MUNIZ-TERRERA (1), Shane SHEEHAN (1), Saturnino LUZ (1), Alison EVANS (2) - (1)University Of Edinburgh, United Kingdom, (2)Alzheimer's Research UK, United Kingdom

**OC39 Predicting the impact of blood biomarkers on cost and wait time in diagnosing treatment-eligible patients for Alzheimer’s disease**
Soeren MATTKE (1), Song Kyu CHO (1), Tobias BITTNER (2), Jakub HLAVKA (1), Mark HANSON (1) - (1)University Of Southern California, United States, (2)F. Hoffmann-La Roche Ltd, Switzerland

**OC40 Neuroimaging-derived Neurite Density and Orientation Dispersion Are More Informative for Predicting Alzheimer’s Clinical Diagnosis than CSF Amyloid and Tau Status Alone**
Rigina Louise GALLAGHER (1), Nagesh ADLURU (1), Nick VOGT (1), Carol A. VAN HULLE (1), Erin JONAITIS (1), Rebecca KOSCIK (1), Steven R. KECSKEMETI (1), Nathaniel A. CHIN (1), Sanjay ASTHANA (1), Gwendlyn KOLLMORGEN (2), Cynthia M. CARLSSON (1), Sterling C. JOHNSON (1), Henrik ZETTERBERG (3), Kaj BLENNOW (3), Andrew L. ALEXANDER (1), Barbara BENDLIN (1) - (1)University Of Wisconsin-Madison, United States, (2)ACADIA Pharmaceuticals, Inc, United States, (3)University Of Gothenburg, Sweden

**OC41 Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease: results from 4 placebo-controlled clinical studies**
Clive BALLARD (1), Erin P. FOFF (2), Pierre TARIOT (3), Bradley MCEVOY (2), Bruce COATE (2), George DEMOS (2), Ana BERRIO (2), Brandon ABBs (2), James M. YOUAKIM (2), Srdjan STANKOVIC (2) - (1)University Of Exeter Medical School, United Kingdom, (2)ACADIA Pharmaceuticals, Inc, United States, (3)Banner Alzheimer's Institute, United States

**OC42 Accounting for Cognitive Practice Effects Results in Earlier Diagnosis and Can Save Millions of Dollars in a Clinical Trial**
William KREMEN (1), Mark SANDERSON-CIMINO (1), Jeremy ELMAN (1), Xin TU (1), Alden GROSS (2), Mark BONDI (1), Amy JAK (1), Michael LYONS (3), Carol FRANZ (1) - (1) UC San Diego, United States, (2)Johns Hopkins University, United States, (3)Boston University, United States

**OC43 The Innate Immune System Modulator GM-CSF/Sargramostim is Safe and Potentially Efficacious in Participants with Mild-to-Moderate Alzheimer’s Disease**
Huntington POTTER (1), Jonathan WOODCOCK (1), Timothy BOYD (1), Stefan SILLAU (1), Christina COUGHLAN (1), John O'SHAUGHNESSY (1), Manuel BORGES (1), Ashesh THAKER (1), Balaibail RAJ (2), Vanessa ADAME (1), Katarzyna ADAMSZUK (3), David SCOTT (3), Heidi CHIAL (1), Helen GRAY (1), Joseph DANIELS (1), Michelle STOCKER (1) - (1)University Of Colorado Anschutz Medical Campus, United States, (2)University Of South Florida, United States, (3)Bioclinica, United States

**OC44 The Alzheimer’s Disease Event Inventory: Analysis of baseline data from the Tauriel study**
Edmond TENG (1), Paul MANSER (1), Geoffrey KERCHNER (2), Michael WARD (1), Karen PICKTHORN (1), Mira BLENDSTRUP (1), Claire LANDSALL (2), Michael KEELEY (1), Fiona MCDougall (1) - (1)Genentech, Inc., United States, (2)F. Hoffmann-La F. Hoffmann-La Roche Ltd, Switzerland
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.15 - 3:00 p.m.</td>
<td>Late breaking communications</td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td>END OF CONFERENCE</td>
</tr>
</tbody>
</table>